永立榮羊水幹細胞新藥 獲再生醫療雙重快速通關認證永立榮 (6973-TW) 今 (22) 日宣布,旗下治療勃起功能障礙新藥 UA002,獲得衛福部 TFDA 核准納入「藥品專案諮詢輔導案件」,並同步取得財團法人藥品查驗中心 CDE「指標案件」資格,未來將在專案輔導機制下,可望加速開發與審查流程、降低開發流程,如同取得再生醫療市場的雙重快速通關認證。 永立榮羊水幹細胞新藥,獲再生醫療雙重快速通關認證。(圖:shutterstock) 永立榮指出,UA002 為自行研發的羊水幹細胞新藥,已完成臨床一期的收案,也已驗證 UA002 的安全性與初步療效,目前正在進行臨床 2a 試驗。 永立榮說明,根據 TFDA「藥品專案諮詢輔導案件」及 CDE「指標案件」輔導機制,主管機關將透過專則窗口,提供從法規策略、臨床試驗設計、製造與品質管制,到上市申請的一站式輔導服務,可大幅縮短藥品開發與審查時程,同時降低開發成本。 永立榮進一步點出,TFDA「藥品專案諮詢輔導要點」已在今年完成修正,正式將再生醫療製劑納入適用範疇,提供明確法規與審查輔導依循。 營運長莊欣怡表示,根據再生醫療雙法,將積極與主管機關密切合作,以有效率的開發路徑推進 UA002 進程。 董事長簡奉任則指出,再生醫療雙法即將上路,對於產業而言是一大激勵,但實施初期需要主管機關明確指引,因此 UA002 獲 TFDA 與 CDE 專案輔導,在主管機關協助下,集中資源加速研發與上市進程。 至於市場現況,根據市場研究機構 Global Markets Insights 報告指出,全球勃起功能障礙藥物自 2025 年起,預估年複合成長率 (CAGR) 達 9.2%,至 2034 年市場規模上看 70 億元。
U-NEURON (6973-TW) announced today (22nd) that its proprietary new drug candidate UA002, designed for the treatment of erectile dysfunction, has been approved by Taiwan TFDA under the "Project-Based Advisory and Guidance Cases" scheme. Concurrently, UA002 secured the "Flagship Project" (Index Case) qualification from the Center for Drug Evaluation (CDE). Under this dedicated advisory framework, the company expects to accelerate development and regulatory review while mitigating R&D risks, marking dual expeditedregulatory support in the regenerative medicine arena.
U-NEURON Chairman Dr. Frank Chien Projects Turnaround to Profitability Next Year
U-NEURON (6973) leverages its world-leading patented amniotic fluid stem cell technology to address the multi-billion-dollar blue ocean market of male erectile dysfunction (ED).
U-NEURON (6973), a biotech companylistedon Taiwan’s Emerging Stock Market, announced on the 3rd that Phase 1 clinical trial enrollment for its novel therapeutic UA002, targeting male erectile dysfunction (ED), has been completed, with Phase 2 trials set to commence.
Regenerative medicine company U-NEURON Biomedical presented its proprietary amniotic fluid stem cell drug candidate UA002 during the Link-J roadshow session prior to BioJapan on October 7. BioJapan is Asia's flagship medical exhibition, serving as an ideal platform for regenerative medicine. The Link-J Global Life Science Session brought together participants from over 10 countries across the Americas, Japan, Europe, Asia, and Australia. Led by the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) of the Ministry of Economic Affairs, the delegation introduced top-performing Taiwanese biomedical companies during the international roadshow.